<div id="readability-page-1"><p>Evernest Financial Advisors LLC raised its stake in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) by 8.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,779 shares of the company's stock after buying an additional 360 shares during the quarter. Eli Lilly and Company comprises  1.4% of Evernest Financial Advisors LLC's portfolio, making the stock its 19th biggest position. Evernest Financial Advisors LLC's holdings in Eli Lilly and Company were worth $3,947,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li></ul><p>A number of other institutional investors and hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC boosted its position in  Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter.  Citizens National Bank Trust Department boosted its stake in shares of  Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the period.  Financial Gravity Asset Management Inc. bought a new position in  Eli Lilly and Company during the first quarter worth $40,000.  Mascagni Wealth Management Inc. bought a new stake in shares of  Eli Lilly and Company during the 4th quarter worth about $43,000.  Finally, O Brien Wealth Partners LLC lifted its position in  Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the last quarter. 82.53% of the stock is owned by institutional investors. </p><h2>Eli Lilly and Company Stock Down 2.6%</h2><p>Shares of NYSE:LLY opened at $746.17 on Thursday. The business has a fifty day simple moving average of $777.97 and a 200 day simple moving average of $800.20. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The firm has a market cap of $707.17 billion, a P/E ratio of 60.71, a P/E/G ratio of 1.09 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. </p><h2>Eli Lilly and Company Announces Dividend</h2><ul><li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li></ul><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 48.82%. </p><h2>Wall Street Analyst Weigh In</h2><p>Several analysts recently weighed in on LLY shares. Morgan Stanley  reissued an &#34;overweight&#34; rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. HSBC lowered Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;reduce&#34; rating and reduced their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim upped their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 11th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an &#34;overweight&#34; rating and a $975.00 price objective for the company. Finally, Erste Group Bank lowered Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, June 5th. One analyst  has rated the stock with a sell rating, three have assigned  a hold rating and seventeen have assigned  a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $1,012.56.</p><ul><li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li></ul><p><b>Get Our Latest Analysis on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Profile</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>How to trade penny stocks: A step-by-step guide</li><li>Buy the Dip? These Earnings Misses Offer Long-Term Upside</li><li>What Investors Need to Know About Upcoming IPOs</li><li>RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?</li><li>How to Calculate Retirement Income: MarketBeat’s Calculator</li><li>How DigitalOcean's Focus Is Fueling Explosive Growth</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Evernest Financial Advisors LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 8.1% in Q1, acquiring an additional 360 shares, bringing its total to 4,779 shares valued at approximately $3.95 million. Eli Lilly represents 1.4% of Evernest's portfolio. The stock is currently down 2.6%, trading at $746.17, with a market cap of $707.17 billion. Analysts have mixed ratings, with an average target price of $1,012.56, indicating a "Moderate Buy" sentiment.</p>

Evernest Financial Advisors LLC Buys 360 Shares of Eli Lilly and Company (NYSE:LLY)